FDA Drugs (New Approvals & NDA)Original article
Non-Compliance Letters under 505B(d)(1) of the Federal Food, Drug, and Cosmetic Act
RegulatoryNegative
AI Analysis
Summary
FDA guidance on sending non-compliance letters to sponsors who fail to submit required pediatric assessments under PREA regulations by the final due date.
Outcome Details
FDA non-compliance letter for failure to submit pediatric assessments under PREA by final due date
Importance:3/10
Sentiment:
-0.30
PREApediatricregulatoryFDAnon-compliance505B(d)(1)
Read the original article
Published by FDA Drugs (New Approvals & NDA) on August 19, 2026 2:28 PM